Vigilare Wealth Management Buys Shares of 5,193 Boston Scientific Corporation $BSX

Key Points

• Vigilare Wealth Management has acquired a new stake of 5,193 shares in Boston Scientific Corporation valued at approximately $558,000 during Q2.
• Insider transactions included sales by EVP Arthur C. Butcher and Director Yoshiaki Fujimori, with a significant portion of shares sold, indicating a 42.32% and 58.23% decrease in their ownership respectively.
• The company reported a 22.8% revenue increase year-over-year for the last quarter, with an EPS of $0.75, surpassing analyst expectations of $0.72.

Vigilare Wealth Management bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,193 shares of the medical equipment provider's stock, valued at approximately $558,000.

A number of other large investors also recently added to or reduced their stakes in BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management raised its position in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 373 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 124,214 shares of company stock valued at $13,048,957. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

NYSE:BSX opened at $97.55 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $103.53 and a 200 day simple moving average of $102.13. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The stock has a market capitalization of $144.54 billion, a PE ratio of 58.07, a P/E/G ratio of 2.34 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the business posted $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on BSX shares. Robert W. Baird raised their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial raised their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Needham & Company LLC restated a "buy" rating and set a $121.00 target price on shares of Boston Scientific in a report on Friday, September 19th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $118.38.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.